Novavax COVID-19 vaccine enters second round of human trials

[admin]

The trial will include 2,665 healthy adults and 240 medically stable adults with HIV.

Novavax COVID-19 vaccine enters second round of human trials : Read more

 

[Chem721]

At least one of these vaccine candidates is using recombinant proteins attached to an inert carrier. This could be superior to genomic approaches as it presents the antigen(s) in a format most easily accessible to the immune system.

Is anyone aware of other vaccines using recombinant SARS-CoV-2 proteins instead of its genome?